On February 17, Global pharma major Lupin Limited announced the launch of Posaconazole Delayed-Release Tablets, 100 mg.
This is followed by it’s alliance partner AET Pharma US Inc. receiving approval for its ANDA from the United States Food and Drug Administration (USFDA).
Moreover, Posaconazole Delayed-Release Tablets are the biological equivalent of Noxafil Delayed-Release Tablets of Merck Sharp & Dohme Corp.
These tablets are used to diagnose patients with Candida infections and forprophylaxis of invasive Aspergillus.
This also includes patients who are susceptible due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients among others.
Further, it’s estimated annual sales was recorded at USD 186 million in the U.S back in December 2020.
However, Lupin Ltd was reportedly trading at Rs 1,077.95 around 12:23 pm with per piece declined by Rs 17.85 or a margin of 1.63 percent.
Previously, the closing of Lupin Ltd on BSE was at Rs 1,095.80.
The share price is moving in an upward trend as it reached its 52-week high at Rs 1,121.85 and 52-week low at Rs 505 last year on 18 September and 13 March respectively.
At present, it is trading below its 52-week high declined by a margin of 3.97 percent and by a margin of 113.33 percent above its 52-week low.
As of today, the share price of Lupin has witnessed a fall by a margin of 2 percent intraday.
Check all the recent news updates and share market updates